Expertise in
23
conditions

Dr. Morie A. Gertz

Hematology
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 
Accepting New Patients
Offers Telehealth
44 Years of Experience
Expertise in
23
conditions
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 

Overview

Morie Gertz is a Hematologist practicing medicine in Rochester, Minnesota. He has been practicing medicine for over 44 years.

Dr. Gertz is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Transplant, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 759 peer reviewed articles and participating in 6 clinical trials. Dr. Gertz is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MN

Hospital Affiliations

Mayo Clinic Health System - Mankato
Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Sanford
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

MN - Cancer Hematology
200 1st St SW, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)
A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug
Study Drug: ANX005
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction
Enrollment Status: Completed
Publish Date: April 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

759 Total Publications

Reply: Biochemical Remission and Residual Cardiac Abnormalities in AL Amyloidosis.
Reply: Biochemical Remission and Residual Cardiac Abnormalities in AL Amyloidosis.
Journal: JACC. CardioOncology
Published: June 28, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ayalew Tefferi is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Tefferi is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Splenectomy, and Bone Marrow Transplant. Dr. Tefferi is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angela Dispenzieri is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Dispenzieri is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, POEMS Syndrome, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dispenzieri is currently accepting new patients.

Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Expertise in
25
conditions
Dr. Stephen M. Ansell
Hematology | Oncology
Referral may be required

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-923-2592
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Ansell is a Hematologist and an Oncologist practicing medicine in Rochester, Minnesota. Dr. Ansell is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Ansell is currently accepting new patients.

Frequently Asked Questions about Dr. Morie A. Gertz

How do I make an appointment with Dr. Morie A. Gertz?

You can book an appointment with Dr. Morie A. Gertz by calling their office at 507-229-0068. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Morie A. Gertz a top-rated expert for Primary Amyloidosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Morie A. Gertz is classified as an Elite expert for Primary Amyloidosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Morie A. Gertz specialize in?

While Dr. Morie A. Gertz is a Hematology, they have specific expertise in Primary Amyloidosis, Multiple Myeloma, and Waldenstrom Macroglobulinemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Morie A. Gertz participate in research or clinical trials?

Yes. Dr. Morie A. Gertz has published 759 articles and abstracts on conditions like Primary Amyloidosis. You can view a list of Dr. Morie A. Gertz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Morie A. Gertz accept my insurance?

Dr. Morie A. Gertz accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 507-229-0068 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gertz's expertise for a condition
ConditionClose
View All 12 Elite Conditions
    View All 11 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile